Axillary-conserving surgery is facilitated by neoadjuvant chemotherapy of breast cancer

被引：13

作者：

Beatty, J. David ^{[1
]}

Precht, Lisa M. ^{[1
]}

Lowe, Kimberly ^{[2
]}

Atwood, Mary ^{[1
]}

机构：

[1] Swedish Med Ctr, Swedish Canc Inst, Seattle, WA USA

[2] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA

来源：

AMERICAN JOURNAL OF SURGERY | 2009年 / 197卷 / 05期

关键词：

Neoadjuvant chemotherapy; Downstaging; Post-chemotherapy sentinel node biopsy; Breast-conserving surgery; Axillary-conserving surgery; SENTINEL-LYMPH-NODE; SURGICAL ADJUVANT BREAST; PREOPERATIVE CHEMOTHERAPY; BIOPSY; ACCURATE; WOMEN;

D O I：

10.1016/j.amjsurg.2008.12.009

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

BACKGROUND: This study examines the downstaging of breast cancer axillary lymph node (ALN) metastasis by neoadjuvant chemotherapy (NCT) and the potential facilitation of axillary-conserving Surgery. METHODS: Records of breast cancer patients treated with NCT, breast surgery, and pathological ALN assessment were reviewed using the institutional breast cancer database. RESULTS: Of 473 cases, 309 (65%) were clinically ALN-positive (cN+) and 164 (35%) were clinically ALN-negative (cN-). Pre-NCT, needle biopsy, sentinel lymph node (SLN) biopsy, or axillary dissection documented metastasis in 94% (117/124) of cN+ and 27% (13/49) of cN- patients tested. Pathological complete response of ALNs to NCT was documented in 36% (41/115) of patients. False negative SLN biopsy following NCT occurred in 4% of cases (1/28). CONCLUSION: NCT downstages primary breast cancer and ALN metastasis. ALN and SLN biopsy following, rather than before, NCT facilitate both breast- and axillary-conserving surgery. (C) 2009 Elsevier Inc. All rights reserved.

引用

页码：637 / 642

页数：6

共 31 条

[1] The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from national surgical adjuvant breast and bowel project protocol B-27 [J].

Bear, HD ;

Anderson, S ;

Brown, A ;

Smith, R ;

Mamounas, EP ;

Fisher, B ;

Margolese, R ;

Theoret, H ;

Soran, A ;

Wickerham, DL ;

Wolmark, N .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (22) :4165-4174

[2] Contrast-enhanced breast magnetic resonance imaging: the surgical perspective [J].

Beatty, J. David ;

Porter, Bruce A. .

AMERICAN JOURNAL OF SURGERY, 2007, 193 (05) :600-605

[3] Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer [J].

Breslin, TM ;

Cohen, L ;

Sahin, A ;

Fleming, JB ;

Kuerer, HM ;

Newman, LA ;

Delpassand, ES ;

House, R ;

Ames, FC ;

Feig, BW ;

Ross, MI ;

Singletary, SE ;

Buzdar, AU ;

Hortobagyi, GN ;

Hunt, KK .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (20) :3480-3486

[4] Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: A National Cancer Institute conference [J].

Buchholz, Thomas A. ;

Lehman, Constance D. ;

Harris, Jay R. ;

Pockaj, Barbara A. ;

Khouri, Nagi ;

Hylton, Nola F. ;

Miller, Michael J. ;

Whelan, Timothy ;

Pierce, Lori J. ;

Esserman, Laura J. ;

Newman, Lisa A. ;

Smith, Barbara L. ;

Bear, Harry D. ;

Mamounas, Eleftherios P. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (05) :791-797

[5] The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes [J].

Carey, Lisa A. ;

Dees, E. Claire ;

Sawyer, Lynda ;

Gatti, Lisa ;

Moore, Dominic T. ;

Collichio, Frances ;

Ollila, David W. ;

Sartor, Carolyn I. ;

Graham, Mark L. ;

Perou, Charles M. .

CLINICAL CANCER RESEARCH, 2007, 13 (08) :2329-2334

[6] Sentinel node biopsy before neoadjuvant chemotherapy for determining axillary status and treatment prognosis in locally advanced breast cancer [J].

Cox, CE ;

Cox, JM ;

White, LB ;

Stowell, NG ;

Clark, JD ;

Allred, N ;

Meyers, M ;

Dupont, E ;

Furman, B ;

Minton, S .

ANNALS OF SURGICAL ONCOLOGY, 2006, 13 (04) :483-490

[7] Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18 [J].

Fisher, B ;

Brown, A ;

Mamounas, E ;

Wieand, S ;

Robidoux, A ;

Margolese, RG ;

Cruz, AB ;

Fisher, ER ;

Wickerham, DL ;

Wolmark, N ;

DeCillis, A ;

Hoehn, JL ;

Lees, AW ;

Dimitrov, NV .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (07) :2483-2493

[8] Sentinel lymph node biopsy after neoadjuvant chemotherapy is accurate in breast cancer patients with a clinically negative axillary nodal status at presentation [J].

Gimbergues, P. ;

Abrial, C. ;

Durando, X. ;

Le Bouedec, G. ;

Cachin, F. ;

Penault-Llorca, F. ;

Mouret-Reynier, M. A. ;

Kwiatkowski, F. ;

Maublant, J. ;

Tchirkov, A. ;

Dauplat, J. .

ANNALS OF SURGICAL ONCOLOGY, 2008, 15 (05) :1316-1321

[9] A comparison of sentinel node biopsy before and after neoadjuvant chemotherapy: timing is important [J].

Jones, JL ;

Zabicki, K ;

Christian, RL ;

Gadd, MA ;

Hughes, KS ;

Lesnikoski, BA ;

Rhei, E ;

Specht, MC ;

Dominguez, FJ ;

Smith, BL .

AMERICAN JOURNAL OF SURGERY, 2005, 190 (04) :517-520

[10] Decreased identification rate of sentinel lymph node after neoadjuvant chemotherapy [J].

Kang, SH ;

Kim, SK ;

Kwon, Y ;

Kang, HS ;

Kang, JH ;

Ro, J ;

Lee, ES .

WORLD JOURNAL OF SURGERY, 2004, 28 (10) :1019-1024

← 1 2 3 4 →